Ribociclib + Nonsteroidal Aromatase Inhibitor Benefits Early Breast Cancer
By Lori Solomon HealthDay Reporter
THURSDAY, March 21, 2024 -- Ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) significantly improves invasive disease-free survival among patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, according to a study published in the March 21 issue of the New England Journal of Medicine.
Dennis Slamon, M.D., Ph.D., from the David Geffen School of Medicine at the University of California in Los Angeles, and colleagues conducted a phase 3 trial in which patients with HR-positive, HER2-negative early breast cancer were randomly assigned (1:1) to receive ribociclib (400 mg per day for three weeks, followed by one week off, for three years) plus an NSAI (letrozole [2.5 mg per day] or anastrozole [1 mg per day] for at least five years) or an NSAI alone.
The researchers observed a significant invasive disease-free survival benefit with ribociclib plus an NSAI versus an NSAI alone. Invasive disease-free survival at three years was 90.4 percent with ribociclib plus an NSAI versus 87.1 percent with an NSAI alone (hazard ratio for invasive disease, recurrence, or death, 0.75). For distant disease-free survival and recurrence-free survival, results also favored ribociclib plus an NSAI. No new safety signals emerged.
"These results support the use of ribociclib in the treatment of HR-positive, HER2-negative early breast cancer," the authors write.
The study was funded by Novartis, the manufacturer of ribociclib.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
USPSTF Recommends Breast Cancer Screening for Women Aged 40 to 75 Years
TUESDAY, April 30, 2024 -- The U.S. Preventive Services Task Force (USPSTF) recommends breast cancer screening for women aged 40 to 75 years, but evidence is insufficient for...
Variation ID'd in Risk for Second Primary Cancer After Breast Cancer
TUESDAY, April 30, 2024 -- The risk for second primary cancer (SPC) after breast cancer (BC) varies with gender, age, and socioeconomic status, according to a study published...
AI Model Reduces False Positives in Screening Mammograms
THURSDAY, April 25, 2024 -- A semiautonomous breast cancer screening system reduces false positives with screening mammograms, according to a study published online April 10 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.